Mechanisms of airway obliteration after lung transplantation

Proceedings of the American Thoracic Society

Volumn 3, Issue 5, 2006, Pages 444-449

  Nicod, Laurent P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adaptive immunity; Dendritic cells; Infections; Innate immunity

Indexed keywords

ALLOANTIGEN; AZITHROMYCIN; CYCLOSPORIN; LEUKOTRIENE RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ALLOIMMUNITY; BRONCHIOLITIS OBLITERANS; CELL PROLIFERATION; CONFERENCE PAPER; DENDRITIC CELL; EPITHELIUM CELL; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; OBSTRUCTIVE AIRWAY DISEASE; PATHOGENESIS; RISK FACTOR;

BRONCHIOLITIS OBLITERANS; GRAFT SURVIVAL; HUMANS; IMMUNITY, NATURAL; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS;

EID: 33745849690     PISSN: 15463222     EISSN: 15463222     Source Type: Journal    
DOI: 10.1513/pats.200601-007AW     Document Type: Conference Paper

References (62)

1. Reynaud AC. Memoire sur l'obliteration des bronches. Mem Acad Med Paris 1835;4:117-167.
2. Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl JMed 1985;312:152-158.
3. Burke CM, Theodore J, Dawkins KD, Yousem SA, Blank N, Billingham ME, Van Kessel A, Jamieson SW, Oyer PE, Baldwin JC, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest 1984;86:824-829.
4. Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, Mauer J, Paradis I, Patterson GA, Smith C, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 1993;12:713-716.
5. Valentine VG, Robbins RC, Berry GJ, Patel HR, Reichenspurner H, Reitz BA, Theodore J. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 1996;15:371-383.
6. Hertz MI, Taylor DO, Trulock EP, Boucek MM, Mohacsi PJ, Edwards LB, Keck BM. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002;21:950-970.
7. Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Husain AN, Hruban RH, Marchevsky A, Ohori NP, Ritter J, Stewart S, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection Lung Rejection Study Group. J Heart Lung Transplant 1996;15:1-15.
8. Halloran PF, Homik J, Goes N, Lui SL, Urmson J, Ramassar V, Cockfield SM. The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997;29:79-81.
9. Boehler A, Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 2003;22:1007-1018.
10. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002;166:440-444.
11. Schulman LL, Weinberg AD, McGregor CC, Suciu-Foca NM, Itescu S. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2001;163:437-442.
12. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002;21:271-281.
13. Bando K, Paradis IL, Similo S, Konishi H, Komatsu K, Zullo TG, Yousem SA, Close JM, Zeevi A, Duquesnoy RJ, et al. Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg 1995;110:4-13. [Discussion: 13-14.]
14. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, Garrity ER. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 1999;159:829-833.
15. Lau CL, Palmer SM, Posther KE, Howell DN, Reinsmoen NL, Massey HT, Tapson VF, Jaggers JJ, D'Amico TA, Davis RD Jr. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000;69:1520-1524.
16. Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen NL. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002;74:799-804.
17. Rabinowich H, Zeevi A, Paradis IL, Yousem SA, Dauber JH, Kormos R, Hardesty RL, Griffith BP, Duquesnoy RJ. Proliferative responses of bronchoalveolar lavage lymphocytes from heart-lung transplant patients. Transplantation 1990;49:115-121.
18. Milne DS, Gascoigne AD, Wilkes J, Sviland L, Ashcroft T, Malcolm AJ, Corris PA. MHC class II and ICAM-1 expression and lymphocyte subsets in transbronchial biopsies from lung transplant recipients. Transplantation 1994;57:1762-1766.
19. Neuringer IP, Mannon RB, Coffman TM, Parsons M, Burns K, Yankaskas JR, Aris RM. Immune cells in a mouse airway model of obliterative bronchiolitis. Am J Respir Cell Mol Biol 1998;19:379-386.
20. Rumbley CA, Silver SJ, Phillips SM. Dependence of murine obstructive airway disease on CD40 ligand. Transplantation 2001;72:1616-1625.
21. Nicod LP, Joudrier S, Isler P, Spiliopoulos A, Pache JC. Upregulation of CD40, CD80, CD83 or CD86 on alveolar macrophages after lung transplantation. J Heart Lung Transplant 2005;24:1067-1075.
22. Suga M, Maclean AA, Keshavjee S, Fischer S, Moreira JM, Liu M. RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration. Am J Respir Crit Care Med 2000;162:1940-1948.
23. Belperio JA, Keane MP, Burdick MD, Lynch JP III, Xue YY, Berlin A, Ross DJ, Kunkel SL, Charo IF, Strieter RM. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001;108:547-556.
24. Medoff BD, Seung E, Wain JC, Means TK, Campanella GS, Islam SA, Thomas SY, Ginns LC, Grabie N, Lichtman AH, et al. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med 2005;202:97-110.
25. Leonard CT, Soccal PM, Singer L, Berry GJ, Theodore J, Holt PG, Doyle RL, Rosen GD. Dendritic cells and macrophages in lung allografts: a role in chronic rejection? Am J Respir Crit Care Med 2000;161:1349-1354.
26. Yousem SA, Ray L, Paradis IL, Dauber JA, Griffith BP. Potential role of dendritic cells in bronchiolitis obliterans in heart-lung transplantation. Ann Thorac Surg 1990;49:424-428.
27. Toews GB. Impact of bacterial infections on airway diseases. Eur Respir Rev 2005;14:62-68.
28. Johnston SL. Impact of viruses on airway diseases. Eur Respir Rev 2005;14:57-61.
29. Nicod LP. Lung defences: an overview. Eur Respir Rev 2005;14:45-50.
30. Ip WKE, Charriere G, Cho JH, Ezekowitz RAB. Receptors and signaling in the innate immune system. Curr Opin Organ Transplant 2005;10:326-333.
31. Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, Schwartz DA. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005;171:780-785.
32. Awad M, Pravica V, Perrey C, El Gamel A, Yonan N, Sinnott PJ, Hutchinson IV. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum Immunol 1999;60:343-346.
33. El-Gamel A, Awad MR, Hasleton PS, Yonan NA, Hutchinson JA, Campbell CS, Rahman AH, Deiraniya AK, Sinnott PJ, Hutchinson IV. Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant 1999;18:517-523.
34. Khalifah AP, Hachem RR, Chakinala MM, Schechtman KB, Patterson GA, Schuster DP, Mohanakumar T, Trulock EP, Walter MJ. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004;170:181-187.
35. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. JHeart Lung Transplant 2002;21:559-566.
36. Garbino J, Gerbase MW, Wunderli W, Kolarova L, Nicod LP, Rochat T, Kaiser L. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004;125:1033-1039.
37. Vilchez RA, McCurry K, Dauber J, Iacono A, Keenan R, Zeevi A, Griffith B, Kusne S. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis 2001;33:2004-2008.
38. Vilchez RA, McCurry K, Dauber J, Lacono A, Griffith B, Fung J, Kusne S. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002;2:287-291.
39. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999;67:315-320.
40. Duncan SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL, Williams PA, Johnson BA, Griffith BP. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994;150:146-152.
41. Milne DS, Gascoigne A, Wilkes J, Sviland L, Ashcroft T, Pearson AD, Malcolm AJ, Corris P. The immunohistopathology of obliterative bronchiolitis following lung transplantation. Transplantation 1992;54:748-750.
42. D'Ovidio F, Mura M, Tsang M, Waddell TK, Hutcheon MA, Singer LG, Hadjiliadis D, Chaparro C, Gutierrez C, Pierre A, et al. Bile acid aspiration and the development of bronchiolitis obliterans after lung transplantation. J Thorac Cardiovasc Surg 2005;129:1144-1152.
43. Belperio JA, Keane MP, Burdick MD, Lynch JP III, Xue YY, Li K, Ross DJ, Strieter RM. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 2002;169:1037-1049.
44. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003;28:12-24.
45. Parks WC. Matrix metalloproteinases in lung repair. Eur Respir J 2003;44(Suppl):36s-38s.
46. Hübner RH, Meffert S, Mundt U, Böttcher H, Freitag S, El Mokhtari NE, Pufe T, Hirt S, Fölsch UR, Bewig B. Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2005;25:494-501.
47. Alho HS, Inkinen KA, Salminen US, Maasilta PK, Taskinen EI, Glumoff V, Vuorio EI, Ikonen TS, Harjula AL. Collagens I and III in a porcine bronchial model of obliterative bronchiolitis. Am J Respir Crit Care Med 2001;164:1519-1525.
48. Aris RM, Walsh S, Chalermskulrat W, Hathwar V, Neuringer IP. Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med 2002;166:417-422.
49. Charpin JM, Stern M, Lebrun G, Aubin P, Grenet D, Israel-Biet D. Increased endothelin-1 associated with bacterial infection in lung transplant recipients. Transplantation 2001;71:1840-1847.
50. Hertz MI, Henke CA, Nakhleh RE, Harmon KR, Marinelli WA, Fox JM, Kubo SH, Shumway SJ, Bolman RM III, Bitterman PB. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci USA 1992;89:10385-10389.
51. Charpin JM, Stern M, Grenet D, Israel-Biet D. Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis. Am J Respir Crit Care Med 2000;161:1991-1998.
52. El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, Campbell C, Rahman A, Sheldon S, Deiraniya A, et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999;18:828-837.
53. Sivakumar B, Harry LE, Paleolog EM. Modulating angiogenesis: more vs less. JAMA 2004;292:972-977.
54. Belperio JA, Keane MP, Burdick MD, Gomperts B, Xue YY, Hong K, Mestas J, Ardehali A, Mehrad B, Saggar R, et al. Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 2005;115:1150-1162.
55. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. JHeart Lung Transplant 2002;21:297-310.
56. Finkelstein SM, Snyder M, Stibbe CE, Lindgren B, Sabati N, Killoren T, Hertz MI. Staging of bronchiolitis obliterans syndrome using home spirometry. Chest 1999;116:120-126.
57. Reynaud-Gaubert M, Marin V, Thirion X, Farnarier C, Thomas P, Badier M, Bongrand P, Giudicelli R, Fuentes P. Upregulation of chemokines in bronchoalveolar lavage fluid as a predictivemarker of post-transplant airway obliteration. J Heart Lung Transplant 2002;21:721-730.
58. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, Lordan JL, Dark JH, Corris PA. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005;172:772-775.
59. Whyte RI, Rossi SJ, Mulligan MS, Florn R, Baker L, Gupta S, Martinez FJ, Lynch JP III. Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg 1997;64:945-948.
60. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, Hardesty RL, Weyant RJ, Griffith BP. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995;60:580-584. [Discussion: 584-585.]
61. Iacono AT, Johnson BA, Wayne F, Grgurich BS, Youssef Georges J, Cocoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006;354:141-150.
62. Gerbase MW, Spiliopoulos A, Rochat T, Archinard M, Nicod LP. Healthrelated quality of life following single or bilateral lung transplantation: a 7-year comparison to functional outcome. Chest 2005;128:1371-1378.